论文部分内容阅读
肺癌以发病率高、死亡率高、5年生存率低位居全球癌症死亡原因的首位,而非小细胞肺癌占肺癌的80%~90%[1],其中腺癌约占38%[2],已超过鳞癌成为最常见的病理类型。迄今为止非小细胞肺癌最有效的根治方式是外科手术,然而约3/4患者初诊时已处于癌症晚期,失去了外科手术的机会。因此,含铂两药化疗是标准一线治疗方案,但其仅能使晚期非小细胞肺癌患者死亡率下降26%~32%,5年生存率<1%[3]。近年来,已发现一些分子的改变与肿瘤的发生机制有关,如
Lung cancer with high incidence, high mortality, low 5-year survival rates among the leading cause of cancer deaths in the world, and non-small cell lung cancer accounts for 80% to 90% of lung cancer [1], of which adenocarcinoma accounts for about 38% [2 ], Has exceeded the squamous cell carcinoma has become the most common pathological type. So far the most effective radical treatment of non-small cell lung cancer is surgery. However, about three-quarters of patients are already in advanced stages of cancer at the time of first visit, losing the chance of surgery. Therefore, platinum-based chemotherapy is the standard first-line treatment, but only in patients with advanced non-small cell lung cancer mortality decreased by 26% to 32%, 5-year survival rate of <1% [3]. In recent years, it has been found that some molecular changes related to tumorigenesis, such as